Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: Implications for visualizing cancer invasion

Journal of Nuclear Medicine

Volumn 53, Issue 1, 2012, Pages 138-145

  Persson, Morten ^a,b,c,d   Madsen, Jacob ^b   Østergaard, Søren ^e   Jensen, Mette Munk ^b,c   Jørgensen, Jesper Tranekjær ^b,c   Juhl, Karina ^d   Lehmann, Charlotte ^d   Ploug, Michael ^a,d   Kjaer, Andreas ^a,b,c  

^a The Danish Chinese Center for Proteases and Cancer   (Denmark)

^b University of Copenhagen   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d FINSEN LABORATORY   (Denmark)

^e NOVO NORDISK A S   (Denmark)

Author keywords

64Cu; Cancer invasion; CD87; Molecular imaging; PET; uPAR

Indexed keywords

ASPARTYLCYCLOHEXYLALANYLGLUTAMINE DEXTRO SERINE DEXTRO ARGINYLTYROSYLEUCYLGLUTAMICYLSERYLAMIDE TETRAXETAN CU 64; ASPARTYLCYCLOHEXYLALANYLPHENYLALANINE DEXTRO SERINE DEXTRO ARGINYLTYROSYLEUCYLTRYPTOPHANYLSERYLAMIDE TETRAXETAN CU 64; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; RADIOPHARMACEUTICAL AGENT; TETRAXETAN; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER INVASION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; NON INVASIVE PROCEDURE; NONHUMAN; PEPTIDE SYNTHESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; RADIOACTIVITY; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; COPPER RADIOISOTOPES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROCYCLIC COMPOUNDS, 1-RING; HT29 CELLS; HUMANS; MICE; NEOPLASM INVASIVENESS; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOCHEMISTRY; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR;

EID: 84855392303     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.083386     Document Type: Article

References (37)

1. Sporn MB. The war on cancer. Lancet. 1996;347:1377-1381. (Pubitemid 26147937)
2. Schmitt M, Mengele K, Napieralski R, et al. Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn. 2010;10:1051-1067.
3. Jacobsen B, Ploug M. The urokinase receptor and its structural homologue C4.4A in human cancer: expression, prognosis and pharmacological inhibition. Curr Med Chem. 2008;15:2559-2573.
4. Romer J, Nielsen BS, Ploug M. The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des. 2004;10:2359-2376. (Pubitemid 38855042)
5. Foekens JA, Peters HA, Look MP, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 2000;60:636-643. (Pubitemid 30094561)
6. Rasch MG, Lund IK, Almasi CE, Hoyer-Hansen G. Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer. Front Biosci. 2008;13:6752-6762.
7. Illemann M, Bird N, Majeed A, et al. Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. Int J Cancer. 2009;124:1860-1870.
8. Nielsen BS, Rank F, Illemann M, Lund LR, Dano K. Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor. Int J Cancer. 2007;120:2086-2095. (Pubitemid 46555845)
9. Dublin E, Hanby A, Patel NK, Liebman R, Barnes D. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma: fibroblastic expression has strong associations with tumor pathology. Am J Pathol. 2000;157:1219-1227.
10. Jankun J, Merrick HW, Goldblatt PJ. Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. J Cell Biochem. 1993;53:135-144. (Pubitemid 23294599)
11. Costantini V, Sidoni A, Deveglia R, et al. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues. Cancer. 1996;77:1079-1088.
12. Fisher JL, Field CL, Zhou H, Harris TL, Henderson MA, Choong PF. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases - a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases. Breast Cancer Res Treat. 2000;61:1-12. (Pubitemid 30440545)
13. 64Cu-labeled linear peptide antagonist by microPET. Clin Cancer Res. 2008;14:4758-4766.
14. Ploug M, Ostergaard S, Gardsvoll H, et al. Peptide-derived antagonists of the urokinase receptor: affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry. 2001;40:12157-12168. (Pubitemid 32946557)
15. Jacobsen B, Gardsvoll H, Juhl Funch G, Ostergaard S, Barkholt V, Ploug M. One-step affinity purification of recombinant urokinase-type plasminogen activator receptor using a synthetic peptide developed by combinatorial chemistry. Protein Expr Purif. 2007;52:286-296. (Pubitemid 46150108)
16. Lin L, Gardsvoll H, Huai Q, Huang M, Ploug M. Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy. J Biol Chem. 2010;285:10982-10992.
17. Rønne E, Hoyer-Hansen G, Brunner N, et al. Urokinase receptor in breast cancer tissue extracts: enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treat. 1995;33:199-207.
18. Gaardsvoll H, Jacobsen B, Kriegbaum MC, et al. Conformational regulation of urokinase receptor (uPAR) function: impact of receptor occupancy and epitopemapped monoclonal antibodies on lamellipodia induction. J Biol Chem. 2011; 286:33544-33556.
19. Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F, Dano K. Cellular receptor for urokinase plasminogen activator: carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem. 1991;266:1926-1933. (Pubitemid 21908387)
20. Riisbro R, Christensen IJ, Piironen T, et al. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res. 2002;8:1132-1141. (Pubitemid 34517650)
21. Ploug M. Structure-function relationships in the interaction between the urokinase- type plasminogen activator and its receptor. Curr Pharm Des. 2003;9:1499-1528. (Pubitemid 36758313)
22. de Bock CE, Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev. 2004;24:13-39. (Pubitemid 38018594)
23. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev. 2008;34:122-136.
24. Knör S, Sato S, Huber T, et al. Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer. Eur J Nucl Med Mol Imaging. 2008;35:53-64. (Pubitemid 350234153)
25. Rabbani SA, Ateeq B, Arakelian A, et al. An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo. Neoplasia. 2010;12:778-788.
26. Schafer JM, Peters DE, Morley T, et al. Efficient targeting of head and neck squamous cell carcinoma by systemic administration of a dual uPA and MMP-activated engineered anthrax toxin. PLoS ONE. 2011;6:e20532.
27. 64Cu-labeled tetrameric RGD peptide. J Nucl Med. 2005;46:1707-1718.
28. 64Cu labeled affibody protein. Bioconjug Chem. 2010;21:947-954.
29. Bass LA, Wang M, Welch MJ, Anderson CJ. In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjug Chem. 2000;11:527-532. (Pubitemid 30597722)
30. 57Co. Int J Rad Appl Instrum B. 1986;13:363-368.
31. Boswell CA, Sun X, Niu W, et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem. 2004;47:1465-1474. (Pubitemid 38327472)
32. Anderson CJ, Wadas TJ, Wong EH, Weisman GR. Cross-bridged macrocyclic chelators for stable complexation of copper radionuclides for PET imaging. Q J Nucl Med Mol Imaging. 2008;52:185-192. (Pubitemid 351721939)
33. Kriegbaum MC, Persson M, Haldager L, et al. Rational targeting of the urokinase receptor (uPAR): development of inhibitors and non-invasive imaging probes. Curr Drug Targets. 2011;12:1711-1728.
34. Llinas P, Le Du MH, Gardsvoll H, et al. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J. 2005; 24:1655-1663. (Pubitemid 40704976)
35. Chen K, Chen X. Positron emission tomography imaging of cancer biology: current status and future prospects. Semin Oncol. 2011;38:70-86.
36. Gutova M, Najbauer J, Gevorgyan A, et al. Identification of uPAR-positive chemoresistant cells in small cell lung cancer. PLoS ONE. 2007;2:e243.
37. Nikolova DA, Asangani IA, Nelson LD, et al. Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: u-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity. Cancer Res. 2009;69:2461-2470.